Literature DB >> 3127819

Lung cancer, immune thrombocytopenia and the lupus inhibitor.

C L Kozlowski1, M J Johnson, D W Gorst, R F Willey.   

Abstract

This case report describes the simultaneous occurrence of autoimmune thrombocytopenia and the lupus anticoagulant in a patient with primary adenocarcinoma of the bronchus. Treatment with corticosteroids and plasmapheresis resulted in a return to normal of the partial thromboplastin time and the disappearance of the platelet antibodies. The carcinoma was inoperable.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3127819      PMCID: PMC2428534          DOI: 10.1136/pgmj.63.743.793

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Autoimmune thrombocytopenic purpura ("ITP" type) with chronic lymphocytic leukemia.

Authors:  S EBBE; B WITTELS; W DAMESHEK
Journal:  Blood       Date:  1962-01       Impact factor: 22.113

2.  A clinical study of the lupus anticoagulant.

Authors:  M A Schleider; R L Nachman; E A Jaffe; M Coleman
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

3.  A comparative analysis of methods suitable for detection of platelet alloantibodies: inhibition of 14C-serotonin uptake, 14C-serotonin release and microcomplement fixation.

Authors:  D Heinrich; C Kessler; C M Mueller-Eckhardt
Journal:  Vox Sang       Date:  1977       Impact factor: 2.144

4.  Lupus-type coagulation inhibitor in hairy cell leukaemia and resolution with splenectomy.

Authors:  A S Duncombe; R G Dalton; G F Savidge
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

5.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

Review 6.  Anti-phospholipid antibodies.

Authors:  E N Harris; A E Gharavi; G R Hughes
Journal:  Clin Rheum Dis       Date:  1985-12

7.  Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.

Authors:  E N Harris; A E Gharavi; U Hegde; G Derue; S H Morgan; H Englert; J K Chan; R A Asherson; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

8.  Thrombosis in patients with the lupus anticoagulant.

Authors:  J R Mueh; K D Herbst; S I Rapaport
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

9.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

10.  Autoimmune basis for visual paraneoplastic syndrome in patients with small-cell lung carcinoma.

Authors:  G B Grunwald; R Klein; M A Simmonds; S E Kornguth
Journal:  Lancet       Date:  1985-03-23       Impact factor: 79.321

View more
  6 in total

Review 1.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

2.  Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.

Authors:  M Blank; J Cohen; V Toder; Y Shoenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Recurrent thrombosis and anticardiolipin antibodies associated with adenocarcinoma of the lung.

Authors:  M N Shaukat; P Hughes
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

Review 4.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 5.  Antiphospholipid syndrome and cancer.

Authors:  Eyal Reinstein; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

6.  Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy.

Authors:  E Zuckerman; E Toubi; T D Golan; T Rosenvald-Zuckerman; E Sabo; Z Shmuel; D Yeshurun
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.